Treatment of epistaxis in Rendu-Osler-Weber disease by in situ Ethibloc injections.
After a brief review of Rendu-Osler-Weber disease, we present the results from a series of 13 patients treated by Ethibloc injections for epistaxis. Based on a review of the literature, typical treatments are presented along with discussion of their efficacy and side effects. In our series, 90% of patients improved after only one injection. All patients reported a decrease in hemorrhage, especially patients with recurrent epistaxis. Five of nine patients reported a decrease in the length of the bleeding episodes. Improvement was reported by 85% of patients within one month following Ethibloc injection. Fifty percent of these patients have persistent good results at 4 Year follow-up. Our results indicate that Ethibloc injections are safe and effective as an alternative treatment for patients that have failed standard treatment options.
Roux-Vaillard
S
S
Service d'Oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale, Centre Hospitalier et Universitaire d'Angers, 49033 Angers cedex 01, France. sroux-vaillard@libertysurf.fr
Pasco-Papon
A
A
Laccourreye
L
L
Dubin
J
J
D000328:Adult; D000368:Aged; D003973:Diatrizoate / Q000627:therapeutic use*; D004338:Drug Combinations; D004844:Epistaxis / Q000188:drug therapy*; D005227:Fatty Acids / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011409:Propylene Glycols / Q000627:therapeutic use*; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy*; D016896:Treatment Outcome; D015028:Zein / Q000627:therapeutic use*
D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D012597:Sclerosing Solutions; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution